Advanced Materials,
Год журнала:
2023,
Номер
36(3)
Опубликована: Ноя. 16, 2023
Lung
cancer
is
the
second
most
prevalent
and
leading
cause
of
cancer-related
death
worldwide.
Surgery,
chemotherapy,
molecular
targeted
therapy,
immunotherapy,
radiotherapy
are
currently
available
as
treatment
methods.
However,
drug
resistance
a
significant
factor
in
failure
lung
treatments.
Novel
therapeutics
have
been
exploited
to
address
complicated
mechanisms
advancement
nanomedicine
extremely
promising
terms
overcoming
resistance.
Nanomedicine
equipped
with
multifunctional
tunable
physiochemical
properties
alignment
tumor
genetic
profiles
can
achieve
precise,
safe,
effective
while
minimizing
or
eradicating
cancer.
Here,
this
work
reviews
discovered
for
radiotherapy,
outlines
novel
strategies
development
against
This
focuses
on
engineering
design,
customized
delivery,
current
challenges,
clinical
translation
application
resistant
Journal of Hematology & Oncology,
Год журнала:
2022,
Номер
15(1)
Опубликована: Март 18, 2022
Abstract
Research
on
tumor
immunotherapy
has
made
tremendous
progress
in
the
past
decades,
with
numerous
studies
entering
clinical
evaluation.
The
cancer
vaccine
is
considered
a
promising
therapeutic
strategy
of
solid
tumors.
Cancer
stimulates
anti-tumor
immunity
antigens,
which
could
be
delivered
form
whole
cells,
peptides,
nucleic
acids,
etc
.
Ideal
vaccines
overcome
immune
suppression
tumors
and
induce
both
humoral
cellular
immunity.
In
this
review,
we
introduced
working
mechanism
summarized
four
platforms
for
development.
We
also
highlighted
research
vaccines,
especially
focusing
their
application
efficacy,
might
hopefully
facilitate
future
design
vaccine.
Signal Transduction and Targeted Therapy,
Год журнала:
2023,
Номер
8(1)
Опубликована: Янв. 6, 2023
Abstract
Recent
advances
in
neoantigen
research
have
accelerated
the
development
and
regulatory
approval
of
tumor
immunotherapies,
including
cancer
vaccines,
adoptive
cell
therapy
antibody-based
therapies,
especially
for
solid
tumors.
Neoantigens
are
newly
formed
antigens
generated
by
cells
as
a
result
various
tumor-specific
alterations,
such
genomic
mutation,
dysregulated
RNA
splicing,
disordered
post-translational
modification,
integrated
viral
open
reading
frames.
recognized
non-self
trigger
an
immune
response
that
is
not
subject
to
central
peripheral
tolerance.
The
quick
identification
prediction
neoantigens
been
made
possible
advanced
next-generation
sequencing
bioinformatic
technologies.
Compared
tumor-associated
antigens,
highly
immunogenic
provide
emerging
targets
personalized
serve
prospective
predictors
survival
prognosis
checkpoint
blockade
responses.
therapies
will
be
aided
understanding
mechanism
underlying
neoantigen-induced
anti-tumor
streamlining
process
neoantigen-based
immunotherapies.
This
review
provides
overview
on
characterization
outlines
clinical
applications
immunotherapeutic
strategies
based
neoantigens.
We
also
explore
their
current
status,
inherent
challenges,
translation
potential.
Signal Transduction and Targeted Therapy,
Год журнала:
2023,
Номер
8(1)
Опубликована: Дек. 13, 2023
With
the
development
and
regulatory
approval
of
immune
checkpoint
inhibitors
adoptive
cell
therapies,
cancer
immunotherapy
has
undergone
a
profound
transformation
over
past
decades.
Recently,
therapeutic
vaccines
have
shown
promise
by
eliciting
de
novo
T
responses
targeting
tumor
antigens,
including
tumor-associated
antigens
tumor-specific
antigens.
The
objective
was
to
amplify
diversify
intrinsic
repertoire
cells.
However,
complete
realization
these
capabilities
remains
an
ongoing
pursuit.
Therefore,
we
provide
overview
current
landscape
in
this
review.
range
antigen
selection,
delivery
systems
strategic
nuances
underlying
effective
presentation
pioneered
vaccine
design.
Furthermore,
review
addresses
status
clinical
trials
discusses
their
strategies,
focusing
on
immunogenicity
anti-tumor
efficacy
assessment.
attempts
toward
developing
not
yielded
breakthrough
outcomes
due
significant
challenges,
microenvironment
suppression,
optimal
candidate
identification,
response
evaluation,
manufacturing
acceleration.
field
is
poised
overcome
hurdles
improve
patient
future
acknowledging
complexities
persistently
striving
surmount
inherent
constraints.
The
advent
of
immunotherapy
has
revolutionized
the
treating
modalities
cancer.
Cancer
vaccine,
aiming
to
harness
host
immune
system
induce
a
tumor-specific
killing
effect,
holds
great
promises
for
its
broad
patient
coverage,
high
safety,
and
combination
potentials.
Despite
promising,
clinical
translation
cancer
vaccines
faces
obstacles
including
lack
potency,
limited
options
tumor
antigens
adjuvants,
immunosuppressive
microenvironment.
Biomimetic
bioinspired
nanotechnology
provides
new
impetus
designing
concepts
vaccines.
Through
mimicking
stealth
coating,
pathogen
recognition
pattern,
tissue
tropism
pathogen,
other
irreplaceable
properties
from
nature,
biomimetic
could
gain
functions
such
as
longstanding,
targeting,
self-adjuvanting,
on-demand
cargo
release.
specific
behavior
endogenous
molecules
each
type
living
entity
(cell
or
microorganism)
offer
unique
features
address
needs
immunotherapy.
In
this
review,
strategies
inspired
by
eukaryotic
cells,
bacteria,
viruses
will
be
overviewed
advancing
vaccine
development.
Our
insights
into
future
development
shared
at
end
expediting
translation.
Cancers,
Год журнала:
2022,
Номер
14(16), С. 3972 - 3972
Опубликована: Авг. 17, 2022
Cancer
immunotherapy
has
revolutionized
the
field
of
oncology
in
recent
years.
Harnessing
immune
system
to
treat
cancer
led
a
large
growth
number
novel
immunotherapeutic
strategies,
including
checkpoint
inhibition,
chimeric
antigen
receptor
T-cell
therapy
and
vaccination.
In
this
review,
we
will
discuss
current
landscape
immuno-oncology
research,
with
focus
on
elements
that
influence
outcomes.
We
also
highlight
advances
basic
aspects
tumor
immunology,
particular,
role
immunosuppressive
cells
within
microenvironment
regulating
antitumor
immunity.
Lastly,
how
understanding
immunology
can
lead
development
new
strategies.
